Ion Beam Applications SA (OTCMKTS:IOBCF – Get Free Report) saw a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 63,862 shares, an increase of 390.2% from the July 15th total of 13,027 shares. Based on an average daily volume of 319 shares, the days-to-cover ratio is presently 200.2 days.
Institutional Investors Weigh In On Ion Beam Applications
Several institutional investors have recently bought and sold shares of the business. EP Wealth Advisors LLC acquired a new stake in shares of Ion Beam Applications in the second quarter worth $271,000. Ieq Capital LLC purchased a new position in shares of Ion Beam Applications in the 2nd quarter valued at $4,072,000. Allworth Financial LP acquired a new position in shares of Ion Beam Applications during the 2nd quarter valued at $190,000. BlackRock Inc. purchased a new stake in Ion Beam Applications during the 2nd quarter worth $488,621,000. Finally, Vise Technologies Inc. acquired a new stake in Ion Beam Applications in the 2nd quarter valued at $590,000. 14.86% of the stock is currently owned by hedge funds and other institutional investors.
Ion Beam Applications Price Performance
OTCMKTS IOBCF opened at $19.00 on Wednesday. Ion Beam Applications has a 1-year low of $11.45 and a 1-year high of $20.10. The business’s 50-day simple moving average is $18.96 and its 200-day simple moving average is $17.78.
About Ion Beam Applications
Ion Beam Applications (OTCMKTS: IOBCF) is a Belgium-based medical technology company specializing in the development and deployment of particle therapy solutions for cancer treatment. Founded in 1986 and headquartered in Louvain-la-Neuve, the company is best known for its Proteus® line of proton therapy systems, which are designed to deliver precise, high-energy particle beams that target tumors while sparing healthy tissue. IBA oversees the full project lifecycle, from system design and manufacturing to installation, commissioning, and ongoing service support.
In addition to its flagship proton therapy business, IBA operates a diversified portfolio of technologies for medical and industrial applications.
Featured Stories
- Five stocks we like better than Ion Beam Applications
- Hims & Hers’ Revenue Beat Came With a Profitability Problem
- A Westinghouse IPO Could Reset the Nuclear Stock Conversation
- Fastly’s Q2 Rally Shows Investors Are Buying the Edge AI Turnaround
- Paramount’s 30-Film Promise Puts AMC Back in the Box Office Conversation
Receive News & Ratings for Ion Beam Applications Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ion Beam Applications and related companies with MarketBeat.com's FREE daily email newsletter.
